Skip to main content

A Review on Liposomes


Definition: An artificial microscopic vesicle consisting of an aqueous core enclosed in one or more phospholipids layers, used to convey vaccines, drugs, enzymes, or other substances to target cells or organs.

Introduction

¡  Liposome was found by Alec Bingham of Babraham Institute in Cambridge, England in 1965.

¡  In 1990, drugs with liposome and Amphotericin B were approved by Ireland.

¡  In 1995 America F.D.A approved liposor doxodubicin.

¡  Liposome is a lipid vesicle suspending in the hydro-phase with a diameter around 0.0025~3.5um. The membrane of liposome is made of phospholipids, which have phosphoric acid sides to form the liposome bilayers.
Composition of liposomes:
A. Phospholipids
The most common natural phospholipid is the phospatidylcholine (PC) is the amphipathic molecule and also known as lecithin.
            Naturally occurring phospholipids used in liposomes are:
       Phosphatidylcholine
       Phosphatidylethanolamine
       Phosphatidylserine
            Synthetic phospholipids used in the liposomes are:
       Dioleoyl phosphatidylcholine
       Disteroyl phosphatidylcholine
       Dioleoyl phosphatidylethanolamine
       Distearoyl phosphatidylethanolamine
B. Cholesterol:  
¡  Cholesterol can be incorporated into phospholipids membrane in very high concentration up to 1:1 or 2:1 molar ratios of cholesterol to phospatidylcholine.
¡  Being an amphipathic molecule, cholesterol inserts into the membrane with its hydroxyl group of cholesterol oriented towards the aqueous surface and aliphatic chain aligned parallel to the acyl chains in the center of the bilayers and also it increase the separation between choline head groups and eliminates the normal electrostatic and hydrogen bonding interaction.
¡ 

The phospholipids are arranged in such a way that the hydrophilic head is exposed outside and the lipophilic tails are aliened inside. This makes the liposomes water soluble molecules.


Advantages :
¡  Biocompatible, completely biodegradable, non-toxic, flexible and non-immunogenic.
¡  Liposomes supply both a lipophilic environment and aqueous “milieu interne” in one system.
¡  Liposomes have the ability to protect their encapsulated drug from the external environment.
¡  Liposomes help to reduce exposure of sensitive tissues to toxic drugs.
¡  Alter the pharmacokinetic and pharmacodynamic property of drugs (reduced elimination, increased circulation life time).
¡  Flexibility to couple with site-specific ligands to achieve active targeting (Anticancer and Antimicrobial drugs).
¡  Liposomes can be formulated into multiple dosage forms.
¡  Liposomes can encapsulate both micro and macromolecules such as hemoglobin, erythropoeitin, interferon g etc.
Disadvantages :
¡  Production cost is high
¡  Leakage and fusion of encapsulated drug / molecules.
¡  Sometimes phospholipids undergoes oxidation and hydrolysis like reaction
¡  Short half-life
¡  Low solubility
Classification :
¡  Based on Structural Parameters:
  1. Multi-laminar vesicles (MLV): made up of series of concentric bi-layer of lipid enclosing a small internal volume with size range > 0.5um.
  2. Oligolamelar vesicles (OLV): constitutes 2 to 10 bi layer of lipids surrounding a large     internal volume with size range of 0.1 – 1um.
  3. Unilamellar vesicle (ULV): single layer of lipids. Based on the size of the single layer they are further divide into the following types with in ULV as
  4. Small unilaminar vesicle: size of 20 to 40 nm
  5. Medium unilaminar vesicle: size of 40 to 80 nm
  6. Large unilaminar vesicle: size of 100 to 1000 nm
  7. Gaint unilaminar vesicle: size of more than 1000 nm
  8. Multivesicular Vesicle(MV): constitutes for multiple vesicles and size range >1um.
     General Structure of various types of liposomes:
General Method of Liposome Preparation:
Different Methods of Preparation
The methods are broadly classified into three classes   according to basic modes of dispersion:
  1. Physical Dispersion
  2. Solvent dispersion
  3. Detergent solubilisation.
Physical Dispersion:
There are four basic methods of physical dispersion:
a)      Hand shaken multilamellar vesicles.
b)      Non shaking vesicles.
c)      Pro – liposomes.
d)      Freeze drying.
Hand Shaking Method:


Non Shaking Method &  Pro - Liposomes:
Buchi Rotatory Evaporator
Freeze Thaw Method:


Dried Reconstituted Vesicles (DRV) and Freeze Thaw Sonication (FTS):
Ethanol / Ether Injection Method:
Reverse Phase Evaporation Vesicles:

Mechanism of incorporation of drug in liposomes:
  1. Encapsulation
  2. Partitioning
  3. Reverse loading
Characterisation of liposomes:
1.
Physical Characterization
S.no 
Characterization parameters
Analytical method/Instrument
1
Vesicle shape and surface morphology
Transmission electron microscopy,
Freeze-fracture electron microscopy
2
   Mean vesicle size and size distribution
   (submicron and micron range)
Dynamic light scattering, zetasizer,
Photon correlation spectroscopy, laser
 light scattering, gel permeation and gel exclusion
3
Surface charge
Free-flow electrophoresis
4
Electrical surface potential and surface pH
Zetapotential measurements & pH sensitive probes
5
Lamellarity
Small angle X-ray scattering, 31P-NMR,
Freeze-fracture electron microscopy
6
Phase behavior
Freeze-fracture electron microscopy, Differential
 scanning colorimetery
7
Percent of free drug/ percent capture
Minicolumn centrifugation, ion-exchange
 chromatography,  radiolabelling
8
Drug release
Diffusion cell/ dialysis

Chemical Characterization
S.No
Characterization parameters
Analytical method/Instrument
1
Phospholipid concentration
Barlett assay, stewart assay, HPLC
2
Cholesterol concentration
Cholesterol oxidase assay and HPLC
3
Phopholipid peroxidation
UV absorbance, Iodometric  and GLC
4
Phospholipid hydrolysis, Cholesterol auto-oxidation.
HPLC and TLC
5
Osmolarity
Osmometer

Biological Characterization
S.No
Characterization parameters
Analytical method/Instrument
1
Sterility
Aerobic or anaerobic cultures
2
Pyrogenicity
Limulus Amebocyte Lysate (LAL) test
3
Animal toxicity
Monitoring survival rates, histology and pathology

Therapeutic applications of liposomes
List of marketed products









Comments

Post a Comment

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

DoE - Doctrine of Equivalents

The Doctrine of Equivalents is a legal principle that is relevant to patent law, particularly in the United States, and it helps protect inventors' rights even when minor changes or substitutions have been made to a patented invention.  When an inventor applies for a patent, the claims in the patent document define the scope of protection for the invention. These claims outline the specific elements or features of the invention that are considered unique and non-obvious. If another party copies or uses the patented invention without permission, it may be considered infringement. However, in some cases, the accused infringer may make slight modifications to the invention that fall outside the literal scope of the patented claims. The Doctrine of Equivalents comes into play here. It allows the patent holder to assert that the accused infringer's modified version is still equivalent to the patented invention and, therefore, falls within the scope of the patent protection. For the

Competitive Landscape for Pharmaceutical Generic products.

Creating a competitive landscape for a pharmaceutical generic product involves analyzing the market and identifying key players, their strengths, weaknesses, and market positioning. Here's a simplified outline: **Competitive Landscape Analysis for Pharmaceutical Generic Product:** 1. **Market Overview:**    - Size of the pharmaceutical generic product market.    - Growth trends and forecasts.    - Regulatory environment and barriers to entry. 2. **Key Players:**    - List the major pharmaceutical companies producing the generic product.    - Include both global and regional players. 3. **Market Share:**    - Percentage of market share held by each major player.    - Trends in market share changes over time. 4. **Product Portfolio:**    - Types of generic products offered by each player.    - Variations in strengths, dosage forms, and delivery methods. 5. ** Competitive Advantage :**    - Identify unique selling points of each player's products.    - Cost advantages, manufacturi